Literature DB >> 23983927

Clozapine-related EEG changes and seizures: dose and plasma-level relationships.

Seema Varma1, Delia Bishara, Frank M C Besag, David Taylor.   

Abstract

Clozapine is a widely used atypical antipsychotic with a unique effectiveness in treatment-resistant schizophrenia. An important adverse effect is seizures, which have been observed at all stages of clozapine treatment. Valproate has traditionally been considered the drug of choice for the prophylaxis of clozapine seizures, however it may not be the most suitable choice for all patients. There is disagreement as to the best point to prescribe valproate or a suitable antiepileptic: as seizure prophylaxis at a certain clozapine dose or level, or only as remedial treatment. In this review, we examine the relevant literature with an aim to evaluate the following relationships: clozapine dose and electroencephalogram (EEG) abnormalities, plasma levels and EEG abnormalities, dose and occurrence of seizures and plasma levels and occurrence of seizures. Weighted linear regression models were fitted to investigate these relationships. There was a strong relationship between clozapine dose and plasma level and occurrence of clozapine-induced EEG abnormalities. However, a statistically significant relationship between dose and occurrence of seizures was not found. A relationship between clozapine plasma level and occurrence of seizures was not established because of the scarcity of useful data although our review found three case reports which suggested that there is a very substantial risk of seizures with clozapine plasma levels exceeding 1300 μg/l. Seizures are more common during the initiation phase of clozapine treatment, suggesting a slow titration to target plasma levels is desirable. An antiepileptic drug should be considered when the clozapine plasma level exceeds 500 μg/l, if the EEG shows clear epileptiform discharges, if seizures, myoclonic jerks or speech difficulties occur and when there is concurrent use of epileptogenic medication. The antiepileptics of choice for the treatment and prophylaxis of clozapine-induced seizures are valproate (particularly where there is mood disturbance) and lamotrigine (where there is resistance to clozapine).

Entities:  

Keywords:  antiepileptic; clozapine; seizure; valproate

Year:  2011        PMID: 23983927      PMCID: PMC3736902          DOI: 10.1177/2045125311405566

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  88 in total

1.  Gabapentin prophylaxis of clozapine-induced seizures.

Authors:  S I Usiskin; R Nicolson; M Lenane; J L Rapoport
Journal:  Am J Psychiatry       Date:  2000-03       Impact factor: 18.112

2.  Clozapine-induced stuttering and seizures.

Authors:  Harpreet S Duggal; K Jagadheesan; S Haque Nizamie
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

3.  Gabapentin for clozapine-related seizures.

Authors:  P Landry
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

4.  Myoclonic seizures and "leg folding" phenomena with clozapine therapy: report of two cases.

Authors:  R E Antelo; J K Stanilla; N Martin-Llonch
Journal:  Biol Psychiatry       Date:  1994-12-01       Impact factor: 13.382

5.  Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.

Authors:  K Wahlbeck; M Cheine; A Essali; C Adams
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

Review 6.  Review and management of clozapine side effects.

Authors:  D D Miller
Journal:  J Clin Psychiatry       Date:  2000       Impact factor: 4.384

Review 7.  Prolonged postictal encephalopathy in two patients with clozapine-induced seizures.

Authors:  L P Karper; S P Salloway; J P Seibyl; J H Krystal
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1992       Impact factor: 2.198

Review 8.  Valproate in psychiatric disorders: literature review and clinical guidelines.

Authors:  S L McElroy; P E Keck; H G Pope; J I Hudson
Journal:  J Clin Psychiatry       Date:  1989-03       Impact factor: 4.384

9.  Outcome following clozapine discontinuation: a retrospective analysis.

Authors:  James M Atkinson; Petrina Douglas-Hall; Catrin Fischetti; Anna Sparshatt; David M Taylor
Journal:  J Clin Psychiatry       Date:  2007-07       Impact factor: 4.384

10.  Clozapine and seizures.

Authors:  E Haller; R L Binder
Journal:  Am J Psychiatry       Date:  1990-08       Impact factor: 18.112

View more
  35 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

Review 2.  Adverse effects of clozapine in older patients: epidemiology, prevention and management.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

Review 3.  Clozapine in primary care.

Authors:  Karl Winckel; Dan Siskind
Journal:  Aust Prescr       Date:  2017-12-04

4.  Variation in dose and plasma level of lamotrigine in patients discharged from a mental health trust.

Authors:  Petrina Douglas-Hall; Olubanke Dzahini; Fiona Gaughran; Ahmed Bile; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-13

5.  Genetic and Clinical Factors Affecting Plasma Clozapine Concentration.

Authors:  Eric Olsson; Gunnar Edman; Leif Bertilsson; Dzana Sudic Hukic; Catharina Lavebratt; Sven V Eriksson; Urban Ösby
Journal:  Prim Care Companion CNS Disord       Date:  2015-02-19

Review 6.  Epilepsy and Psychiatric Comorbidities: Drug Selection.

Authors:  Marco Mula
Journal:  Curr Treat Options Neurol       Date:  2017-10-19       Impact factor: 3.598

Review 7.  Clozapine as a Model for Antipsychotic Development.

Authors:  Frederick C Nucifora; Marina Mihaljevic; Brian J Lee; Akira Sawa
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

Review 8.  Seizure associated with clozapine: incidence, etiology, and management.

Authors:  Andrew M Williams; Susie H Park
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 9.  Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series.

Authors:  Cana Aksoy Poyraz; Şenol Turan; Ömer Faruk Demirel; Nazife Gamze Usta Sağlam; Nazım Yıldız; Alaattin Duran
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

10.  Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.

Authors:  D J Siskind; M Harris; A Phillipou; V A Morgan; A Waterreus; C Galletly; V J Carr; C Harvey; D Castle
Journal:  Epidemiol Psychiatr Sci       Date:  2016-07-18       Impact factor: 6.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.